Stock Track | Harrow Health Plunges 13.25% Post-Market on Earnings Miss and Weak 2026 Guidance

Stock Track
03/03

Harrow Health Inc. (HROW) experienced a significant post-market plunge of 13.25% on Monday.

The sharp decline followed the company's release of its fourth-quarter 2025 financial results, which revealed earnings that fell significantly short of analyst expectations. Harrow reported Q4 earnings per share of $0.17, missing the FactSet consensus estimate of $0.37 by a wide margin.

Adding to investor concerns, the company issued its 2026 revenue guidance in the range of $350 million to $365 million, which is substantially below the analyst consensus expectation of approximately $386 million to $391 million. This combination of an earnings miss and weaker-than-anticipated forward outlook prompted the post-market selloff.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10